This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing. IMforte [NCT05091567] is a Phase III, open-label, randomized trial evaluating the ...

Preclinical data show that Sail’s eRNA vaccine candidates induce robust anti-malaria immune responses and protect against infection in a mouse challenge model ...

Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitor ...

PASADENA, CA, USA I June 02, 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a ...

SEOUL, South Korea I June 02, 2025 I ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S.

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China ...

NEW YORK, NY, USA and MAINZ, GERMANY I May 28, 2025 I Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that they ...

Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA ®, the Company’s approved respiratory ...

BASEL, Switzerland I June 1, 2025 I Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety ...

TOKYO, Japan and Cambridge, UK I June 02, 2025 I Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a ...

COPENHAGEN, Denmark I June 2, 2025 I Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and ...

SHANGHAI, China I June 1, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...